Frontline T-Cell Engager vs Autologous Stem Cell Transplant and Measurable Residual Disease (MRD)-Guided Sequential Intensification Therapy in Multiple Myeloma

Protocol No

SCRI-FASTER-MM195

Staff Member

Ravi Narra

Phase

Summary

This project is being done to determine if using the combination of elranatamab and daratumumab is as effective as ASCT with lenalidomide and daratumumab for the treatment of MM while causing fewer side effects than ASCT with lenalidomide and daratumumab.

Objective

Study of t-cell engager vs. stem cell transplant and MRD-guided therapy in multiple myeloma

Status

OPEN TO ACCRUAL